Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma.
Immunotherapy
Lung cancer
NTCU-mouse model
RNASeq
Squamous
Syngeneic cell lines
Journal
Disease models & mechanisms
ISSN: 1754-8411
Titre abrégé: Dis Model Mech
Pays: England
ID NLM: 101483332
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
received:
27
05
2021
accepted:
29
11
2021
pubmed:
7
12
2021
medline:
1
4
2022
entrez:
6
12
2021
Statut:
ppublish
Résumé
There is a paucity of adequate mouse models and cell lines available to study lung squamous cell carcinoma (LUSC). We have generated and characterized two models of phenotypically different transplantable LUSC cell lines, i.e. UN-SCC679 and UN-SCC680, derived from A/J mice that had been chemically induced with N-nitroso-tris-chloroethylurea (NTCU). Furthermore, we genetically characterized and compared both LUSC cell lines by performing whole-exome and RNA sequencing. These experiments revealed similar genetic and transcriptomic patterns that may correspond to the classic LUSC human subtype. In addition, we compared the immune landscape generated by both tumor cells lines in vivo and assessed their response to immune checkpoint inhibition. The differences between the two cell lines are a good model for the remarkable heterogeneity of human squamous cell carcinoma. Study of the metastatic potential of these models revealed that both cell lines represent the organotropism of LUSC in humans, i.e. affinity to the brain, bones, liver and adrenal glands. In summary, we have generated valuable cell line tools for LUSC research, which recapitulates the complexity of the human disease.
Identifiants
pubmed: 34870316
pii: 273637
doi: 10.1242/dmm.049137
pmc: PMC8822220
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2022. Published by The Company of Biologists Ltd.
Déclaration de conflit d'intérêts
Competing interests R.K. is founder of PearlRiver Bio (now part of Centessa Pharmaceuticals), founder of NEO New Oncology (now part of Siemens Healthcare), and received consulting honoraria from PearlRiver Bio and NEO New Oncology. L.M.M. received a research grant from Astra-Zeneca and BMS, and is a licensed patent co-holder on Complement in LC early detection in AMADIX.
Références
Mol Oncol. 2019 May;13(5):1092-1109
pubmed: 30747484
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Cell. 2018 Apr 5;173(2):371-385.e18
pubmed: 29625053
J Thorac Oncol. 2016 Apr;11(4):524-36
pubmed: 26845193
Int J Cancer. 2019 Jan 1;144(1):49-58
pubmed: 29978474
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
Cancer Res. 2004 Mar 1;64(5):1647-54
pubmed: 14996723
Cancer Med. 2019 Apr;8(4):1459-1466
pubmed: 30773851
Nat Genet. 2012 Oct;44(10):1104-10
pubmed: 22941188
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Science. 2018 Oct 12;362(6411):
pubmed: 30309915
Cancer Lett. 2019 Aug 10;457:168-179
pubmed: 31078738
Int J Mol Sci. 2020 Jul 30;21(15):
pubmed: 32751497
PLoS One. 2015 Apr 28;10(4):e0124283
pubmed: 25919140
Nat Commun. 2021 Mar 5;12(1):1482
pubmed: 33674596
Oncogene. 2017 Apr 20;36(16):2243-2254
pubmed: 27819679
Cancer Prev Res (Phila). 2012 Feb;5(2):283-9
pubmed: 22086679
Nat Commun. 2014 Mar 27;5:3518
pubmed: 24670920
Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):E11671-E11680
pubmed: 30487219
Dis Markers. 2020 Aug 31;2020:8825997
pubmed: 32934754
Exp Ther Med. 2018 Dec;16(6):4991-5002
pubmed: 30542454
Gan. 1977 Jun;68(3):343-52
pubmed: 913956
Clin Cancer Res. 2019 Jun 15;25(12):3528-3537
pubmed: 30833271
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Bone. 2013 Jan;52(1):532-9
pubmed: 23142363
Eur J Nucl Med Mol Imaging. 2004 May;31(5):740-51
pubmed: 15014901
Carcinogenesis. 2012 Jul;33(7):1270-6
pubmed: 22510280
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Cancer Res. 1981 Dec;41(12 Pt 1):5027-32
pubmed: 7307005
Nat Cancer. 2020 Jan;1(1):75-85
pubmed: 35121837
Genes Dev. 2020 Aug 1;34(15-16):1017-1032
pubmed: 32747478
In Vitro. 1980 Oct;16(10):884-92
pubmed: 7419233
Nat Rev Cancer. 2018 Mar;18(3):139-147
pubmed: 29326431
Acta Biochim Biophys Sin (Shanghai). 2014 Feb;46(2):100-11
pubmed: 24374773
Onco Targets Ther. 2019 Oct 15;12:8437-8445
pubmed: 31686860
Ann Thorac Med. 2017 Jul-Sep;12(3):191-198
pubmed: 28808491
Nature. 2012 Sep 27;489(7417):519-25
pubmed: 22960745
Proc Natl Acad Sci U S A. 2019 May 14;116(20):9999-10008
pubmed: 31028147
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
J Cell Biochem. 2019 Dec 5;:
pubmed: 31803961
Tumour Biol. 2015 Mar;36(3):2111-9
pubmed: 25613063
Clin Cancer Res. 2012 Feb 15;18(4):1167-76
pubmed: 22228640
Sci Rep. 2015 Oct 27;5:14237
pubmed: 26503331
J Natl Compr Canc Netw. 2019 Dec;17(12):1464-1472
pubmed: 31805526